Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281484 | 0.77 | CA9 (0.39) | CA9PTGS2CA12KMT2APDGFRA | |
| SCHEMBL3180645 | 0.69 | CA9 (0.43) | CA9 | |
| SCHEMBL7645920 | 0.67 | KMT2A (0.43) | PTGS2PDE4BGSK3BKMT2APDGFRA | |
| SCHEMBL8187039 | 0.66 | CA9 (0.41) | CA9 | |
| SCHEMBL3183012 | 0.64 | CA9 (0.50) | CA9CA12KMT2AMEN1ALDH1A1 | |
| SCHEMBL1384629 | 0.63 | KDM4E (0.47) | CA9CA12GSK3BKMT2AMEN1 | |
| SCHEMBL4278162 | 0.63 | CA9 (0.38) | CA9 | |
| SCHEMBL8783438 | 0.63 | CLK4 (0.43) | CA9PTGS2CA12PDE4BGSK3B | |
| SCHEMBL3188444 | 0.62 | CA9 (0.34) | CA9 | |
| SCHEMBL94149 | 0.62 | GSK3B (0.58) | PTGS2PDE4BGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2859961-A2 | Methods and compositions for metal nanoparticle treated surfaces | Avent, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-7662957-B2 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-7408059-B2 | 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide; cyclizing a beta-ketoamide-N-sulfonic acid with an acid anhydride | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| WO-2007095058-A2 | METHODS AND COMPOSITIONS FOR METAL NANOPARTICLE TREATED SURFACES | ACRYMED, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | DAICEL CHEMICAL INDUSTRIES, LTD. | 2005-08-18 | — | — | US | disclosed |
| EP-1564211-A1 | Method for producing 3,4-Dihydro-1,2,3-Oxathiazin-4-one-2,2-Dioxide compound or salt thereof | Daicel Chemical Industries, Ltd. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | CA2, HAO2, SRD5A2 | CA9 124/4885PTGS2 144/4885CA12 37/4885 |
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885PTGS2 2397/4885CA12 923/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885PTGS2 2397/4885CA12 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.